NASDAQ:SNGX Soligenix (SNGX) Stock Price, News & Analysis $2.39 -0.07 (-2.85%) Closing price 02/14/2025 03:59 PM EasternExtended Trading$2.35 -0.04 (-1.67%) As of 02/14/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Soligenix Stock (NASDAQ:SNGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Soligenix alerts:Sign Up Key Stats Today's Range$2.31▼$2.4650-Day Range$2.27▼$3.5952-Week Range$1.83▼$14.92Volume39,956 shsAverage Volume618,514 shsMarket Capitalization$6.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSoligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.Read More… Soligenix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreSNGX MarketRank™: Soligenix scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Soligenix. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Soligenix are expected to grow in the coming year, from ($4.65) to ($2.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soligenix is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soligenix is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoligenix has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Soligenix's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.82% of the float of Soligenix has been sold short.Short Interest Ratio / Days to CoverSoligenix has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soligenix has recently decreased by 65.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSoligenix does not currently pay a dividend.Dividend GrowthSoligenix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.82% of the float of Soligenix has been sold short.Short Interest Ratio / Days to CoverSoligenix has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soligenix has recently decreased by 65.09%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News SentimentN/A News SentimentSoligenix has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Soligenix this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for SNGX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows2 people have added Soligenix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Soligenix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of Soligenix is held by insiders.Percentage Held by InstitutionsOnly 3.60% of the stock of Soligenix is held by institutions.Read more about Soligenix's insider trading history. Receive SNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter. Email Address SNGX Stock News HeadlinesSoligenix settles debt with Pontifax lendersFebruary 10, 2025 | msn.comSoligenix Repays Loan, Boosting Financial FlexibilityFebruary 10, 2025 | tipranks.comCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.February 18, 2025 | Behind the Markets (Ad)Soligenix on Way to Bio Conference in NYCFebruary 4, 2025 | baystreet.caSoligenix to Present at BIO CEO & Investor ConferenceFebruary 4, 2025 | prnewswire.comSoligenix (NASDAQ: $SNGX) Unveils Two-Pronged Approach To Tackle Rare Diseases & Unmet Medical NeedsJanuary 23, 2025 | msn.comSoligenix to Present at Upcoming Investor ConferencesJanuary 16, 2025 | prnewswire.comSNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…January 14, 2025 | msn.comSee More Headlines SNGX Stock Analysis - Frequently Asked Questions How have SNGX shares performed this year? Soligenix's stock was trading at $2.69 at the beginning of the year. Since then, SNGX shares have decreased by 11.2% and is now trading at $2.39. View the best growth stocks for 2025 here. How were Soligenix's earnings last quarter? Soligenix, Inc. (NASDAQ:SNGX) announced its earnings results on Friday, November, 12th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.92) by $0.48. The biopharmaceutical company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.80 million. Soligenix had a negative net margin of 1,473.38% and a negative trailing twelve-month return on equity of 223.29%. When did Soligenix's stock split? Soligenix's stock reverse split on Thursday, June 6th 2024. The 1-16 reverse split was announced on Thursday, June 6th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. Who are Soligenix's major shareholders? Soligenix's top institutional investors include Geode Capital Management LLC (1.04%). Insiders that own company stock include Christopher J Schaber and Richard Straube. View institutional ownership trends. How do I buy shares of Soligenix? Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Soligenix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Soligenix investors own include Tonix Pharmaceuticals (TNXP), Trevena (TRVN), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), T2 Biosystems (TTOO), iBio (IBIO) and Dynavax Technologies (DVAX). Company Calendar Last Earnings11/12/2021Today2/17/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNGX CUSIPN/A CIK812796 Webwww.soligenix.com Phone(609) 538-8200Fax609-452-6467Employees20Year Founded1987Profitability EPS (Most Recent Fiscal Year)($7.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,140,000.00 Net Margins-1,473.38% Pretax Margin-2,220.75% Return on Equity-223.29% Return on Assets-74.18% Debt Debt-to-Equity RatioN/A Current Ratio2.28 Quick Ratio2.28 Sales & Book Value Annual Sales$840,000.00 Price / Sales7.14 Cash FlowN/A Price / Cash FlowN/A Book Value$3.83 per share Price / Book0.62Miscellaneous Outstanding Shares2,510,000Free Float2,440,000Market Cap$6.00 million OptionableNot Optionable Beta1.83 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:SNGX) was last updated on 2/18/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredAre We Headed for a Market Implosion?The world's biggest tech companies are silently sounding the alarm. While everyday investors keep piling in...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.